Precision Neurosurgery specialist company Elekta will be showcasing its Leksell®Vantage™ Stereotactic System at the AANS annual congress.
Background
The Leksell®Vantage™ Stereotactic System is Elekta’s next-generation system for target localization and coordinate referencing for precision neurosurgery. The Leksell Vantage head frame is constructed of a novel epoxy composite and is designed to improve imaging quality, speed and patient comfort in neurosurgery procedures.
Vantage received CE Mark clearance in March 2017 and will be used this month in clinical practice for the first time in Europe at University Hospital La Timone (Marseilles, France), The Academic Medical Center (Amsterdam, the Netherlands), The National Hospital for Neurology and Neurosurgery, Queens Square (London, England) and Karolinska University Hospital (Stockholm, Sweden). The system is currently pending 510(k) clearance with the U.S. FDA.
In addition to Vantage, Elekta will highlight its Leksell Gamma Knife® radiosurgery system. The most clinically studied stereotactic radiosurgery platform, Gamma Knife was highlighted in more than 15 scientific presentations at AANS
Company comments
“Our Leksell Stereotactic System has been helping clinicians achieve outstanding patient outcomes for more than 60 years, and Vantage improves upon this gold standard platform to deliver uncompromising accuracy in stereotactic imaging and treatment,” says Jesper Söderqvist, Vice President Neuroscience Portfolio at Elekta. “With potential for faster imaging, more efficient workflow, reduced artifacts and a better overall user experience, Leksell Vantage is a welcome advancement for physicians and their patients.”
Source: PR Newswire
published: April 24, 2017 in: Clinical Studies/Trials, Congresses and Meetings, Neuro